参考文献

［1］DAGER W E，GULSETH M P，NUTESCU E A.抗凝治疗医护指南［M］.师少军，吕永宁，译.北京：人民卫生出版社,2012.

［2］李家增,王鸿利,包承鑫.抗血栓药和溶血栓药临床应用［M］.北京：科学技术文献出版社,2009.

［3］GARCIA D A，BAGLIN T P，WEITZ J I，et al. Parenteral anticoagulants:Antithrombotic Therapy and Prevention of Thrombosis，9th ed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines［J］. Chest，2012，141（2 Suppl）: e24S-e43S.

［4］付朝宏，黄寿吾，顾其胜，等.血浆肝素浓度测定［J］.血栓与止血学杂志，1994（2）:73-75,82.

［5］ALBADA J，NIEUWENHUIS H K，SIXMA J J. Pharmacokinetics of standard and low molecular weight heparin［M］//Lane D A,Lindahl U.Heparin:chemical and biological properties,clinical applications. London: Edward Arnold,1989:417-431.

［6］洪霞，单培仁，黄伟剑，等.基于体重的肝素负荷剂量下体重指数对活化凝血时间的影响［J］.心电与循环，2012，31（2）:74-76.

［7］ALBAN S. From heparins to factor Ⅹa inhibitors and beyond［J］.Eur J Clin Invest，2005，35 Suppl 1: 12-20.

［8］MOUSA S A，MANNA M. Pharmacokinetic differences among unfractionated heparin and low molecular weight heparins:Impact in patients with renal impairment［M］//PIYATHILAKE D E，LIANG R. Heparin:properties,uses and side effects. New York: Nova Science Publishers，2012:179-195.

［9］GRAY E，HOGWOOD J，MULLOY B. The anticoagulant and antithrombotic mechanisms of heparin［J］. Handb Exp Pharmacol，2012（207）: 43-61.

［10］WONG G C，GIUGLIANO R P，ANTMAN E M. Use of low-molecularweight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention［J］.JAMA，2003，289（3）: 331-342.

［11］松田保.抗凝固疗法［J］.综合临床,2003，52（5）:1621-1623.

［12］ENGELBERG H，沈志祥.肝素、肝素成份和动脉粥样硬化［J］.国外医学.心血管疾病分册，1986（1）: 13-16.

［13］蒋婷婷，孙佳凤，夏江燕，等.肝素酶在内毒素血症致大鼠血管内皮糖萼破坏中的作用.中华麻醉学杂志，2015，35（9）:1131-1131.

［14］王建军,黄寿吾,杨石强,等.肝素对小鼠实验性内毒素血症的保护作用［J］.河南医学研究,1995（01）:7-9.

［15］POMIN V H. Sulfated glycans in inflammation［J］. Eur J Med Chem，2015，92: 353-369.

［16］LEAN Q Y，ERI R D，RANDALL-DEMLLO S，et al. Orally administered enoxaparin ameliorates acute colitis by reducing macrophage-associated inflammatory responses［J］. PLoS One，2015，10（7）: e0134259.

［17］HUANG J N，TSAI M C，FANG S L，et al. Low-molecular-weight heparin and unfractionated heparin decrease Th-1，2，and 17 expressions［J］. PLoS One，2014，9（11）: e109996.

［18］FALANGA A，PANOVA-NOEVA M，RUSSO L. Procoagulant mechanisms in tumour cells［J］. Best Pract Res Clin Haematol，2009，22（1）: 49-60.

［19］PONERT J M，GOCKEL L M，HENZE S，et al. Unfractionated and Low Molecular Weight Heparin Reduce Platelet Induced Epithelial-Mesenchymal Transition in Pancreatic and Prostate Cancer Cells. Molecules. 2018; 23（10）

［20］LEBEAU B，CHASTANG C，BRECHOT J M，et al. Subcutaneous heparin treatment increases survival in small cell lung cancer.“Petites Cellules” Group［J］. Cancer，1994，74（1）: 38-45.

［21］KIERAN M W，KALLURI R，CHO Y J. The VEGF pathway in cancer and disease: responses，resistance，and the path forward［J］. Cold Spring Harb Perspect Med，2012，2（12）:a006593.

［22］LEUNG D W，CACHIANES G，KUANG W J，et al. Vascular endothelial growth factor is a secreted angiogenic mitogen［J］.Science，1989，246（4935）: 1306-1309.

［23］WANG X X. The development of new drug targeting hepcidin［J］.Chin Pharm J，2018，53（6）:405-410．

［24］STRELL C，ENTSCHLADEN F. Extravasation of leukocytes in comparison to tumor cells［J］. Cell Commun Signal，2008，6: 10.

［25］BORSIG L，WONG R，FERAMISCO J，et al. Heparin and cancer revisited: mechanistic connections involving platelets，P-selectin，carcinoma mucins，and tumor metastasis［J］. Proc Natl Acad Sci U S A，2001，98（6）: 3352-3357.

［26］BORSIG L，WONG R，HYNES R O，et al. Synergistic effects of L-and P-selectin in facilitating tumor metastasis can involve non-mucin ligands and implicate leukocytes as enhancers of metastasis［J］. Proc Natl Acad Sci U S A，2002，99（4）: 2193-2198.

［27］YEUNG K T，YANG J. Epithelial-mesenchymal transition in tumor metastasis［J］. Mol Oncol，2017，11（1）: 28-39.

［28］RICKLES F R，PATIERNO S，FERNANDEZ P M. Tissue factor，thrombin，and cancer［J］. Chest，2003，124（3 Suppl）:58S-68S.

［29］WEILER J M，YURT R W，FEARON D T，et al. Modulation of the formation of the amplification convertase of complement，C3b，Bb，by native and commercial heparin［J］. J Exp Med，1978，147（2）: 409-421.

［30］BAUGH C W，LEVINE M，CORNUTT D，et al. Anticoagulant Reversal Strategies in the Emergency Department Setting:Recommendations of a Multidisciplinary Expert Panel［J］. Ann Emerg Med，2020，76（4）: 470-485.

［31］TOMASELLI G F，MAHAFFEY K W，CUKER A，et al. 2017 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants: a report of the American College of Cardiology Task Force on expert consensus decision pathways［J］. J Am Coll Cardiol，2017，70（24）: 3042-3067.

［32］BOER C，MEESTERS M I，VEERHOEK D，et al. Anticoagulant and side-effects of protamine in cardiac surgery: a narrative review［J］. Br J Anaesth，2018，120（5）: 914-927.

［33］SOKOLOWSKA E，KALASKA B，MIKLOSZ J，et al. The toxicology of heparin reversal with protamine: past，present and future［J］.Expert Opin Drug Metab Toxicol，2016，12（8）: 897-909.

［34］APPLEFIELD D，KRISHNAN S. PROTAMINE ［M］. Treasure Island（FL）: StatPearls ，2020.

［35］CARR J A，SILVERMAN N. The heparin-protamine interaction.A review［J］. J Cardiovasc Surg（Torino），1999，40（5）: 659-666.

［36］KITANI T，NAGARAJAN S C，SHANBERGE J N. Effect of protamine on heparin antithrombin Ⅲ complexes. In vivo studies［J］.Thromb Res，1980，17（3/4）: 375-382.

［37］OKAJIMA Y，KANAYAMA S，MAEDA Y，et al. Studies on the neutralizing mechanism of antithrombin activity of heparin by protamine［J］. Thromb Res，1981，24（1/2）: 21-29.

［38］STEHLE G，WUNDER A，SINN H，et al. Complexes of a modified low-molecular-weight heparin with protamine are predominantly cleared by a macrophage scavenger receptormediated process in rats［J］. J Surg Res，1995，58（2）: 197-204.

［39］PAI M，CROWTHER M A. Neutralization of heparin activity［J］.Handb Exp Pharmacol，2012（207）: 265-277.

［40］SIMON E M，STREITZ M J，SESSIONS D J，et al. Anticoagulation reversal［J］. Emerg Med Clin North Am，2018，36（3）: 585-601.

［41］MOCHIZUKI T，OLSON P J，SZLAM F，et al. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass［J］. Anesth Analg，1998，87（4）: 781-785.

［42］BARSTAD R M，STEPHENS R W，HAMERS M J，et al. Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity［J］. Thromb Haemost，2000，83（2）:334-337.

［43］BOLLIGER D，SZLAM F，AZRAN M，et al. The anticoagulant effect of protamine sulfate is attenuated in the presence of platelets or elevated factor Ⅷ concentrations［J］. Anesth Analg，2010，111（3）: 601-608.

［44］KHAN N U，WAYNE C K，BARKER J，et al. The effects of protamine overdose on coagulation parameters as measured by the thrombelastograph［J］. Eur J Anaesthesiol，2010，27（7）: 624-627.

［45］NI AINLE F，PRESTON R J，JENKINS P V，et al. Protamine sulfate down-regulates thrombin generation by inhibiting factorⅤ activation［J］. Blood，2009，114（8）: 1658-1665.

［46］OLSSON A，ALFREDSSON J，HåKANSSON E，et al. Protamine reduces whole blood platelet aggregation after cardiopulmonary bypass［J］. Scand Cardiovasc J，2016，50（1）: 58-63.

［47］KIMMEL S E，SEKERES M，BERLIN J A，et al. Mortality and adverse events after protamine administration in patients undergoing cardiopulmonary bypass［J］. Anesth Analg，2002，94（6）: 1402-1408，table of contents.

［48］KATZ N M，KIM Y D，SIEGELMAN R，et al. Hemodynamics of protamine administration. Comparison of right atrial，left atrial，and aortic injections［J］. J Thorac Cardiovasc Surg，1987，94（6）: 881-886.

［49］NYBO M，MADSEN J S. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review［J］. Basic Clin Pharmacol Toxicol，2008，103（2）: 192-196.

［50］SAITO T，SUMITHRAN E，GLASGOW E F，et al. The enhancement of aminonucleoside nephrosis by the co-administration of protamine［J］. Kidney Int，1987，32（5）: 691-699.

［51］VEHASKARI V M，ROOT E R，GERMUTH F G JR，et al. Glomerular charge and urinary protein excretion: effects of systemic and intrarenal polycation infusion in the rat［J］. Kidney Int，1982，22（2）: 127-135.

［52］HIRD R B，WAKEFIELD T W，MUKHERJEE R，et al. Direct effects of protamine sulfate on myocyte contractile processes.Cellular and molecular mechanisms［J］. Circulation，1995，92（9 Suppl）: Ⅱ433-Ⅱ446.

［53］HORROW J C. Protamine: a review of its toxicity［J］. Anesth Analg，1985，64（3）: 348-361.

［54］CHUDASAMA S L，ESPINASSE B，HWANG F，et al. Heparin modifies the immunogenicity of positively charged proteins［J］.Blood，2010，116（26）: 6046-6053.

［55］WEISS M E，NYHAN D，PENG Z K，et al. Association of protamine IgE and IgG antibodies with life-threatening reactions to intravenous protamine［J］. N Engl J Med，1989，320（14）:886-892.

［56］MOREL D R，LOWENSTEIN E，NGUYENDUY T，et al. Acute pulmonary vasoconstriction and thromboxane release during protamine reversal of heparin anticoagulation in awake sheep.Evidence for the role of reactive oxygen metabolites following nonimmunological complement activation［J］. Circ Res，1988，62（5）: 905-915.

［57］BUTTERWORTH J，LIN Y A，PRIELIPP R，et al. The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers［J］. Anesth Analg，2002，94（3）:514-522; table of contents.

［58］GALEONE A，ROTUNNO C，GUIDA P，et al. Monitoring incomplete heparin reversal and heparin rebound after cardiac surgery［J］. J Cardiothorac Vasc Anesth，2013，27（5）: 853-858.

［59］国家食品药品监督管理总局.总局关于修订鱼精蛋白注射液说明书的公告（2016年第53号） ［A/OL］.（2016-03-09）［2022-11-03］.https://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20160309160601840.html

［60］陈桐，陈庆伟.血小板第四因子与心脑血管疾病［J］.现代医药卫生，2008，24（12）:1842-1843.

［61］杜顺波，方利华.老年多灶性脑梗死患者血浆血小板第4因子变化及其临床意义［J］.中国老年学杂志，2015，35（23）:6756-6757.

［62］MIXON T A，DEHMER G J. Recombinant platelet factor 4 for heparin neutralization［J］. Semin Thromb Hemost，2004，30（3）: 369-377.

［63］COOK J J，NIEWIAROWSKI S，YAN Z，et al. Platelet factor 4 efficiently reverses heparin anticoagulation in the rat without adverse effects of heparin-protamine complexes［J］. Circulation，1992，85（3）: 1102-1109.

［64］DEHMER G J，FISHER M，TATE D A，et al. Reversal of heparin anticoagulation by recombinant platelet factor 4 in humans［J］.Circulation，1995，91（8）: 2188-2194.

［65］DEHMER G J，LANGE R A，TATE D A，et al. Randomized trial of recombinant platelet factor 4 versus protamine for the reversal of heparin anticoagulation in humans［J］. Circulation，1996，94（9 Suppl）: Ⅱ347-Ⅱ352.

［66］HEDNER U. Recombinant activated factor Ⅶ: 30 years of research and innovation［J］. Blood Rev，2015，29 Suppl 1:S4-S8.

［67］VAVRA K A，LUTZ M F，SMYTHE M A. Recombinant factorⅦa to manage major bleeding from newer parenteral anticoagulants［J］. Ann Pharmacother，2010，44（4）: 718-726.

［68］YOUNG G，YONEKAWA K E，NAKAGAWA P A，et al. Recombinant activated factor Ⅶ effectively reverses the anticoagulant effects of heparin，enoxaparin，fondaparinux，argatroban，and bivalirudin ex vivo as measured using thromboelastography［J］. Blood Coagul Fibrinolysis，2007，18（6）: 547-553.

［69］SIEGAL D M，CURNUTTE J T，CONNOLLY S J，et al. Andexanet alfa for the reversal of factor Ⅹa inhibitor activity［J］. N Engl J Med，2015，373（25）: 2413-2424.

［70］MANENO J N，NESS G L. Andexanet alfa，the possible alternative to protamine for reversal of unfractionated heparin［J］. Ann Pharmacother，2021，55（2）: 261-264.

［71］LAULICHT B，BAKHRU S，LEE C，et al. Small molecule antidote for anticoagulants ［J］. Circulation，2012，126（Suppl 21）: 11395.

［72］ANSELL J E，BAKHRU S H，LAULICHT B E，et al. Use of PER977 to reverse the anticoagulant effect of edoxaban［J］. N Engl J Med，2014，371（22）: 2141-2142.

［73］ANSELL J E，LAULICHT B E，BAKHRU S H，et al. Ciraparantag safely and completely reverses the anticoagulant effects of low molecular weight heparin［J］. Thromb Res，2016，146: 113-118.

［74］WEITZ J I，EIKELBOOM J W. Ciraparantag for enoxaparin reversal: Adding to the evidence［J］. Thromb Res，2016，146:106-107.